Agency Forms Undergoing Paperwork Reduction Act Review, 67366 [2010-27604]
Download as PDF
<![CDATA[
67366
Federal Register / Vol. 75, No. 211 / Tuesday, November 2, 2010 / Notices
Dated: October 27, 2010.
Carol Walker,
Acting Reports Clearance Officer, Centers for
Disease Control and Prevention.
[FR Doc. 2010–27601 Filed 11–1–10; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
[30-Day–11–0307]
Agency Forms Undergoing Paperwork
Reduction Act Review
The Centers for Disease Control and
Prevention (CDC) publishes a list of
information collection requests under
review by the Office of Management and
Budget (OMB) in compliance with the
Paperwork Reduction Act (44 U.S.C.
chapter 35). To request a copy of these
requests, call 404–639–4604 or send
comments to Carol Walker, CDC Acting
Reports Clearance Officer, 1600 Clifton
Road, MS–D74, Atlanta, GA 30333 or
send an e-mail to omb@cdc.gov. Send
written comments to CDC Desk Officer,
Office of Management and Budget,
Washington, DC or by fax to (202) 395–
5806. Written comments should be
received within 30 days of this notice.
Proposed Project
Gonococcal Isolate Surveillance
Project (GISP), (OMB No. 0920–0307)—
Extension—National Center for HIV/
AIDS, Viral Hepatitis, STD, and TB
Prevention (NCHHSTP), Centers for
Disease Control and Prevention (CDC).
Background and Brief Description
CDC is requesting a 3-year extension
without change for this project. The
objectives of GISP are to monitor trends
in antimicrobial susceptibility of
Neisseria gonorrhoeae strains in the
U.S. and to characterize resistant
isolates. Monitoring antibiotic
susceptibility is critical since Neisseria
gonorrhoeae has demonstrated the
consistent ability to gain antibiotic
resistance. GISP provides critical
surveillance for antimicrobial
resistance, allowing for informed
treatment recommendations.
This project involves 5 regional
laboratories and 30 sexually transmitted
disease (STD) clinics operated by the
local health departments around the
country. The STD clinics submit up to
25 gonococcal isolates per month to the
Regional laboratories to measure
susceptibility to a panel of antibiotics.
Limited demographic and clinical
information corresponding to the
isolates are submitted directly by the
STD clinics to CDC.
During 1986–2009, GISP has
demonstrated the ability to effectively
achieve its objectives. The emergence of
resistance in the United States to
penicillin, tetracyclines, and
fluoroquinolones among N. gonorrhoeae
isolates was identified through GISP.
Increased prevalence of
fluoroquinolone-resistant N.
gonorrhoeae (QRNG), as documented by
GISP data, prompted CDC to update the
treatment recommendations for
gonorrhea in CDC’s Sexually
Transmitted Diseases Treatment
Guidelines, 2006 and to release an
MMWR article stating that CDC no
longer recommended fluoroquinolones
for treatment of gonococcal infections.
There are no costs to respondents other
than their time. Respondents receive
Federal funds to participate in this
project. The total annual burden is
estimated to be 8,568 hours.
Number of
responses per
respondent
Number of
respondents
Average burden
per response
(in hours)
Type of respondent
Form name
Clinic .........................................................
Laboratory .................................................
Form 1 ......................................................
Form 2 ......................................................
Form 3 ......................................................
30
5
5
240
1,440
48
11/60
1
12/60
Total ...................................................
...................................................................
40
............................
............................
Dated: October 27, 2010.
Carol Walker,
Acting Reports Clearance Officer, Centers for
Disease Control and Prevention.
[FR Doc. 2010–27604 Filed 11–1–10; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Agency for Healthcare Research and
Quality
hsrobinson on DSK69SOYB1PROD with NOTICES
Agency Information Collection
Activities: Proposed Collection;
Comment Request
DATES: Comments on this notice must be
received by December 2, 2010.
Agency for Healthcare Research
and Quality, HHS.
ACTION: Notice.
AGENCY:
SUMMARY: This notice announces the
intention of the Agency for Healthcare
Research and Quality (AHRQ) to request
that the Office of Management and
Budget (OMB) approve the proposed
VerDate Mar<15>2010
18:39 Nov 01, 2010
Jkt 223001
information collection project: ‘‘AHRQ
Grants Reporting System (GRS).’’ In
accordance with the Paperwork
Reduction Act, 44 U.S.C. 3501–3520,
AHRQ invites the public to comment on
this proposed information collection.
This proposed information collection
was previously published in the Federal
Register on August 31st, 2010 and
allowed 60 days for public comment. No
comments were received. The purpose
of this notice is to allow an additional
30 days for public comment.
Written comments should
be submitted to: AHRQ’s OMB Desk
Officer by fax at (202) 395–6974
(attention: AHRQ’s desk officer) or by email at OIRA_submission@omb.eop.gov
(attention: AHRQ’s desk officer).
Copies of the proposed collection
plans, data collection instruments, and
specific details on the estimated burden
ADDRESSES:
PO 00000
Frm 00023
Fmt 4703
Sfmt 4703
can be obtained from the AHRQ Reports
Clearance Officer.
FOR FURTHER INFORMATION CONTACT:
Doris Lefkowitz, AHRQ Reports
Clearance Officer, (301) 427–1477, or by
e-mail at
doris.lefkowitz@AHRQ.hhs.gov.
SUPPLEMENTARY INFORMATION:
Proposed Project
AHRQ Grants Reporting System (GRS)
AHRQ seeks to renew the Agency’s
Grants Reporting System (GRS), a
systematic method for its grantees to
report project progress and important
preliminary findings for grants funded
by the Agency. This system was first
approved by OMB on November 10,
2004 (OMB Control Number 0935–
0122). The system addressed the
shortfalls in the previous reporting
process and established a consistent and
comprehensive grants reporting solution
for AHRQ. The GRS provides a
centralized repository of grants research
E:\FR\FM\02NON1.SGM
02NON1
]]>Agencies
[Federal Register Volume 75, Number 211 (Tuesday, November 2, 2010)]
[Notices]
[Page 67366]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2010-27604]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
[30-Day-11-0307]
Agency Forms Undergoing Paperwork Reduction Act Review
The Centers for Disease Control and Prevention (CDC) publishes a
list of information collection requests under review by the Office of
Management and Budget (OMB) in compliance with the Paperwork Reduction
Act (44 U.S.C. chapter 35). To request a copy of these requests, call
404-639-4604 or send comments to Carol Walker, CDC Acting Reports
Clearance Officer, 1600 Clifton Road, MS-D74, Atlanta, GA 30333 or send
an e-mail to omb@cdc.gov. Send written comments to CDC Desk Officer,
Office of Management and Budget, Washington, DC or by fax to (202) 395-
5806. Written comments should be received within 30 days of this
notice.
Proposed Project
Gonococcal Isolate Surveillance Project (GISP), (OMB No. 0920-
0307)--Extension--National Center for HIV/AIDS, Viral Hepatitis, STD,
and TB Prevention (NCHHSTP), Centers for Disease Control and Prevention
(CDC).
Background and Brief Description
CDC is requesting a 3-year extension without change for this
project. The objectives of GISP are to monitor trends in antimicrobial
susceptibility of Neisseria gonorrhoeae strains in the U.S. and to
characterize resistant isolates. Monitoring antibiotic susceptibility
is critical since Neisseria gonorrhoeae has demonstrated the consistent
ability to gain antibiotic resistance. GISP provides critical
surveillance for antimicrobial resistance, allowing for informed
treatment recommendations.
This project involves 5 regional laboratories and 30 sexually
transmitted disease (STD) clinics operated by the local health
departments around the country. The STD clinics submit up to 25
gonococcal isolates per month to the Regional laboratories to measure
susceptibility to a panel of antibiotics. Limited demographic and
clinical information corresponding to the isolates are submitted
directly by the STD clinics to CDC.
During 1986-2009, GISP has demonstrated the ability to effectively
achieve its objectives. The emergence of resistance in the United
States to penicillin, tetracyclines, and fluoroquinolones among N.
gonorrhoeae isolates was identified through GISP. Increased prevalence
of fluoroquinolone-resistant N. gonorrhoeae (QRNG), as documented by
GISP data, prompted CDC to update the treatment recommendations for
gonorrhea in CDC's Sexually Transmitted Diseases Treatment Guidelines,
2006 and to release an MMWR article stating that CDC no longer
recommended fluoroquinolones for treatment of gonococcal infections.
There are no costs to respondents other than their time. Respondents
receive Federal funds to participate in this project. The total annual
burden is estimated to be 8,568 hours.
----------------------------------------------------------------------------------------------------------------
Number of Average burden
Type of respondent Form name Number of responses per per response
respondents respondent (in hours)
----------------------------------------------------------------------------------------------------------------
Clinic............................. Form 1............... 30 240 11/60
Laboratory......................... Form 2............... 5 1,440 1
Form 3............... 5 48 12/60
-----------------------------------------------------
Total.......................... ..................... 40 ................ ................
----------------------------------------------------------------------------------------------------------------
Dated: October 27, 2010.
Carol Walker,
Acting Reports Clearance Officer, Centers for Disease Control and
Prevention.
[FR Doc. 2010-27604 Filed 11-1-10; 8:45 am]
BILLING CODE 4163-18-P
